LT3143011T - Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų - Google Patents

Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų

Info

Publication number
LT3143011T
LT3143011T LTEP15725253.7T LT15725253T LT3143011T LT 3143011 T LT3143011 T LT 3143011T LT 15725253 T LT15725253 T LT 15725253T LT 3143011 T LT3143011 T LT 3143011T
Authority
LT
Lithuania
Prior art keywords
heterocyclic compounds
deuterated
imagining agents
imagining
deuterated heterocyclic
Prior art date
Application number
LTEP15725253.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jan Marik
Joseph P. Lyssikatos
Simon Williams
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LT3143011T publication Critical patent/LT3143011T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
LTEP15725253.7T 2014-05-13 2015-05-12 Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų LT3143011T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (1)

Publication Number Publication Date
LT3143011T true LT3143011T (lt) 2021-05-10

Family

ID=53269446

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15725253.7T LT3143011T (lt) 2014-05-13 2015-05-12 Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų

Country Status (21)

Country Link
US (4) US10076581B2 (enExample)
EP (2) EP3143011B1 (enExample)
JP (2) JP6529986B2 (enExample)
KR (2) KR102618139B1 (enExample)
CN (2) CN110483522B (enExample)
AU (2) AU2015261008B2 (enExample)
CA (1) CA2948721C (enExample)
DK (1) DK3143011T3 (enExample)
ES (1) ES2867814T3 (enExample)
HR (1) HRP20210641T1 (enExample)
HU (1) HUE053939T2 (enExample)
IL (3) IL280791B2 (enExample)
LT (1) LT3143011T (enExample)
MX (2) MX376163B (enExample)
PL (1) PL3143011T3 (enExample)
PT (1) PT3143011T (enExample)
RS (1) RS61810B1 (enExample)
RU (1) RU2696492C2 (enExample)
SG (2) SG10201805628TA (enExample)
SI (1) SI3143011T1 (enExample)
WO (1) WO2015173225A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3143011T (lt) 2014-05-13 2021-05-10 F. Hoffmann-La Roche Ag Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
MY196981A (en) 2016-07-22 2023-05-16 Ac Immune Sa Compounds for imaging tau protein aggregates
EP3535265A4 (en) * 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解
EP3853234B1 (en) 2018-09-18 2025-04-23 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CA3110113A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
IL316875A (en) 2018-10-05 2025-01-01 Annapurna Bio Inc Compounds and compositions for treating conditions associated with APJ receptor activity
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
TWI751548B (zh) * 2019-05-09 2022-01-01 瑞士商赫孚孟拉羅股份公司 經標記之咪唑并[1,2-a]嘧啶之合成
CN114867727B (zh) 2019-07-17 2025-02-21 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
CN120187452A (zh) 2022-06-13 2025-06-20 基因泰克公司 使用克瑞尼珠单抗延迟或预防阿尔茨海默病的发作的方法
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD76515A (enExample) *
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
CN101522624B (zh) * 2006-03-30 2013-11-06 宾夕法尼亚大学理事会 苯乙烯基吡啶衍生物及其用于结合和成像淀粉样蛋白斑的用途
EP2727915B1 (en) 2007-09-13 2016-04-13 Concert Pharmaceuticals Inc. Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
US20100144657A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
ES2797523T3 (es) 2009-03-23 2020-12-02 Lilly Co Eli Agentes de obtención de imagen para detectar trastornos neurológicos
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
NZ610315A (en) * 2010-11-15 2015-08-28 Univ Leuven Kath Antiviral condensed heterocyclic compounds
ES2792830T3 (es) * 2012-05-22 2020-11-12 Lilly Co Eli Agentes para formación de imagen en base a carbolina y carbazol, para la detección de disfunción neurológica
CN105358558B (zh) * 2013-10-08 2017-09-26 豪夫迈·罗氏有限公司 作为tau‑pet‑配体的二氮杂咔唑衍生物
LT3143011T (lt) 2014-05-13 2021-05-10 F. Hoffmann-La Roche Ag Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų

Also Published As

Publication number Publication date
AU2015261008A1 (en) 2016-11-17
US20160250358A1 (en) 2016-09-01
HRP20210641T1 (hr) 2021-05-28
IL248692A0 (en) 2017-01-31
MX376163B (es) 2025-03-07
CN110483522B (zh) 2022-05-03
PT3143011T (pt) 2021-04-26
IL271631B (en) 2021-05-31
JP6681498B2 (ja) 2020-04-15
IL280791B2 (en) 2024-03-01
KR102618139B1 (ko) 2023-12-27
DK3143011T3 (da) 2021-05-03
US10675367B2 (en) 2020-06-09
CA2948721C (en) 2023-03-28
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
US20190201561A1 (en) 2019-07-04
MX2016014615A (es) 2017-03-06
NZ764181A (en) 2023-11-24
CN106459059A (zh) 2017-02-22
JP2017515856A (ja) 2017-06-15
AU2019203369A1 (en) 2019-06-06
CN106459059B (zh) 2019-09-24
WO2015173225A1 (en) 2015-11-19
KR20170002639A (ko) 2017-01-06
BR112016026443A2 (pt) 2017-08-15
AU2015261008B2 (en) 2019-02-14
US20230218782A1 (en) 2023-07-13
IL280791B1 (en) 2023-11-01
US11504440B2 (en) 2022-11-22
PL3143011T3 (pl) 2021-07-19
EP3143011B1 (en) 2021-03-03
RU2016147742A (ru) 2018-06-18
RS61810B1 (sr) 2021-06-30
KR20230035445A (ko) 2023-03-13
EP3143011A1 (en) 2017-03-22
ES2867814T3 (es) 2021-10-20
CA2948721A1 (en) 2015-11-19
SI3143011T1 (sl) 2021-08-31
RU2016147742A3 (enExample) 2018-10-08
IL271631A (en) 2020-02-27
KR102530129B1 (ko) 2023-05-10
US12214058B2 (en) 2025-02-04
AU2019203369B2 (en) 2020-06-04
BR112016026443A8 (pt) 2021-07-06
US20200297875A1 (en) 2020-09-24
JP2019147825A (ja) 2019-09-05
JP6529986B2 (ja) 2019-06-12
HUE053939T2 (hu) 2021-08-30
MX2020010847A (es) 2021-07-16
EP3901145A1 (en) 2021-10-27
CN110483522A (zh) 2019-11-22
IL280791A (en) 2021-04-29
US10076581B2 (en) 2018-09-18
MX384604B (es) 2025-03-14
SG11201609281UA (en) 2016-12-29
NZ726208A (en) 2023-11-24
IL248692B (en) 2020-01-30

Similar Documents

Publication Publication Date Title
LT3143011T (lt) Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3331877T (lt) Pirazolpirimidino dariniai ir jų panaudojimas
LT3221306T (lt) Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
GB201403093D0 (en) Therapeutic compounds and their use
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
LT3129019T (lt) Artemizinino junginių ir gefirino agonistų medicininis panaudojimas
HUE054245T2 (hu) Immunszupresszáns formuláció
LT3197898T (lt) Nauji imidazopiridazino junginiai ir jų panaudojimas
IL251904A0 (en) Apilimod for use in the treatment of melanoma
DK3193840T3 (da) Arimoclomol-formulering
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
IL264445A (en) Compounds and compositions and uses thereof
CL2016002705A1 (es) Formulación agroquímica
DK3148513T3 (da) Ceritinib-formulering
FR3021528B1 (fr) Formulation cosmetique
DK3193856T3 (da) Formulering
EP3181125C0 (en) CAPSULE FORMULATION
ES1119005Y (es) Prenda reversible desmontable
LT3518927T (lt) 1-fenilpropanono junginiai ir jų panaudojimas
TH1701000764A (th) สูตรผสมฆ่าเชื้อและการใช้งานของสูตรผสมนั้น
TH1501005156A (th) สารประกอบเฮทเทอโรไซคลิก และการใช้ของสารเหล่านี้
GB201413411D0 (en) Novel compounds and their use
TH1501006596A (th) สารประกอบไบเฮทเทอโรแอริล และการใช้งานของพวกมัน